Business Monitor International


Finland Pharmaceuticals & Healthcare Report

Published 08 December 2014

  • 71 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Finland Pharmaceuticals & Healthcare Report

BMI View: Finland, like many other W estern countries, has a mature pharmaceutical m arket where growth is slowing. Although an ag e ing population will drive the demand for high-value medicines for the treatment of long-term illnesses, drug manufacturers will be pressured to reduce drug prices as the government increases its cost-containment measures. Political uncertain ty along with the country ' s weak economic outlook adds further downward pressure to our forecast.

Headline Expenditure Projections

  • Pharmaceuticals: EUR2.98bn (USD3.93bn) in 2013 to EUR3.04bn (USD4.07bn) in 2014;+2.0% in local currency terms  and 3.6% in US dollar terms. Forecast in line with last quarter .

  • Healthcare: EUR18.40bn (USD24.29bn) in 2013 to EUR18.95bn (USD25.39bn) in 2014; +3.0% in local currency terms and 4.5% in US dollar terms. Forecast in line with last quarter .

Risk/Reward Index

Finland's Risk/Reward Index score is unchanged from Q414 at 68.8 out of 100. This places the country eighth in our rankings in terms of attractiveness to investors. Finland's strong emphasis on the regulatory environment is an appealing feature of the market, although a major factor affecting the business environment for drugmakers is its small overall market size. Nevertheless, given high per capita drug expenditure, companies operating in the country can see substantial incomes.

Key Trends And Developments

November

  • UK-based GE Healthcare has opened Health Innovation Village, its first health tech startup campus in Helsinki, Finland. Already about 20 health tech startup companies operating in the fields of wireless technologies, sensors as well as applications and cloud services, have presence in the country's capital. The Health Innovation Village, which was founded by GE Healthcare Finland's Managing Director Didier Deltort, and Head of finance Mikko Kauppinen, is launched to create an ecosystem for domestic health tech startups to help them innovate and grow. Health tech accounts...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Industry Forecast
13
Pharmaceutical Market Forecast
13
Table: Pharmaceutical Sales, Historical Data And Forecasts (Finland 2010-2018)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Finland 2010-2018)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Finland 2010-2018)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Finland 2010-2018)
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Finland 2010-2018)
20
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Finland 2010-2018)
22
Generic Drug Market Forecast
23
OTC Medicine Market Forecast
24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Finland 2010-2018)
25
Pharmaceutical Trade Forecast
26
Table: Pharmaceutical Trade Data And Forecasts (Finland 2012-2018)
27
Table: Pharmaceutical Trade Data And Forecasts local currency (Finland 2012-2018)
27
Key Risks To BMI's Forecast Scenario
28
Macroeconomic Forecasts
29
Economic Analysis
29
Real GDP By Expenditure
29
Risks To Outlook
33
Table: GDP By Expenditure (Finland 2011-2018)
33
Industry Risk Reward Ratings
34
Western Europe Risk/Reward Ratings
34
Finland Risk/Reward Ratings
40
Rewards
40
Risks
40
Market Overview
42
Industry Trends And Developments
43
Industry Trends And Developments
43
Epidemiology
43
Health Insurance
46
Research & Development
50
Clinical Trials
51
Regulatory Development
52
Pricing & Reimbursement
54
Intellectual Property
57
Competitive Landscape
59
Table: PIF Members
61
Company Developments
61
Demographic Forecast
64
Table: Finland's Population By Age Group, 1990-2020 ('000)
65
Table: Finland's Population By Age Group, 1990-2020 (% of total)
66
Table: Finland's Key Population Ratios, 1990-2020
67
Table: Finland's Rural And Urban Population, 1990-2020
67
Glossary
68
Methodology
70
Pharmaceutical Expenditure Forecast Model
70
Healthcare Expenditure Forecast Model
70
Notes On Methodology
71
Risk/Reward Ratings Methodology
72
Ratings Overview
73
Table: Pharmaceutical Risk/Reward Ratings Indicators
73
Indicator Weightings
74

The Finland Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Finland Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Finnish pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Finland to test other views - a key input for successful budgeting and strategic business planning in the Finnish pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Finnish pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Finland.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc